Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.
When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.
Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/
#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne
Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda - Biotech Industry Examiner
The target is a leukemia drug developer. The real objective is something larger: time, diversification, and a more believable post-Keytruda growth story.
Roche touts near-complete suppression of multiple sclerosis relapse for injectable Ocrevus—Lilly eyes Zepbound label expansion after clearing phase III sleep apnea study—3 patent expirations in 2024 and how companies are pivoting--
http://bit.ly/w28kSd #roche #ms #multiplesclerosis #elililly #zepbound #sleepapnea #patents #patentcliff #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma
Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.
J&J focuses on newer meds to offset Stelara patent cliff —Many patients keep weight off after stopping anti-obesity meds: study — Lilly says gene therapy restores hearing for child with genetic hearing loss--
http://bit.ly/w28kSd #jnj #patents #patentcliff #obesity #novonordisk #hearingloss #elililly #genetherapy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharmaCafepharma
Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.
Industry Examiner
cafepharma